BR0013866A - Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicos - Google Patents

Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicos

Info

Publication number
BR0013866A
BR0013866A BR0013866-5A BR0013866A BR0013866A BR 0013866 A BR0013866 A BR 0013866A BR 0013866 A BR0013866 A BR 0013866A BR 0013866 A BR0013866 A BR 0013866A
Authority
BR
Brazil
Prior art keywords
cationic liposomes
distribution
blood vessels
taxane
angiogenic blood
Prior art date
Application number
BR0013866-5A
Other languages
English (en)
Inventor
Donald M Mcdonald
John W Mclean
O Gavin Thurston
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR0013866A publication Critical patent/BR0013866A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"DISTRIBUIçãO DE LIPOSSOMAS CATIÈNICOS DE TAXANOS AOS VASOS SANGuìNEOS ANGIOGêNICOS". As células endoteliais angiogênicas são seletivamente alvejadas com complexos de lipídio/DNA ou lipossomas catiónicos contendo uma substância que afeta as células alvejadas através da inibição ou promoção de seu crescimento. Um local de angiogênese pode ser precisamente localizado através da administração de lipossomas catiónicos contendo um rótulo detectável. Os complexos podem compreender construções de nucleotideos que são compreendidas por promotores que são seletiva e exclusivamente ativados no ambiente de uma célula endotelial angiogênica.
BR0013866-5A 1999-09-09 2000-09-08 Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicos BR0013866A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39297699A 1999-09-09 1999-09-09
PCT/US2000/024579 WO2001017508A1 (en) 1999-09-09 2000-09-08 Cationic liposome delivery of taxanes to angiogenic blood vessels

Publications (1)

Publication Number Publication Date
BR0013866A true BR0013866A (pt) 2002-05-14

Family

ID=23552795

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013866-5A BR0013866A (pt) 1999-09-09 2000-09-08 Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicos

Country Status (21)

Country Link
US (1) US20100226970A1 (pt)
EP (1) EP1210065B1 (pt)
JP (2) JP4848113B2 (pt)
KR (1) KR100591767B1 (pt)
CN (1) CN1235567C (pt)
AT (1) ATE324867T1 (pt)
AU (1) AU782714B2 (pt)
BR (1) BR0013866A (pt)
CA (1) CA2383412C (pt)
CZ (1) CZ2002850A3 (pt)
DE (1) DE60027730T2 (pt)
EA (1) EA005923B1 (pt)
EE (1) EE200200127A (pt)
ES (1) ES2258471T3 (pt)
HK (1) HK1046506B (pt)
HU (1) HUP0202669A3 (pt)
IL (2) IL148372A0 (pt)
MX (1) MXPA02002579A (pt)
PL (1) PL203128B1 (pt)
WO (1) WO2001017508A1 (pt)
ZA (1) ZA200201555B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL366025A1 (en) * 2000-05-03 2005-01-24 Munich Biotech Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
ATE345775T1 (de) * 2001-10-03 2006-12-15 Celator Pharmaceuticals Inc Zusammensetzungen zur verabreichung von arzneimittelkombinationen
ES2330326T3 (es) 2002-05-24 2009-12-09 Angiotech International Ag Composiciones y metodos para recubrir implantes medicos.
EP1374864A1 (en) * 2002-06-26 2004-01-02 Munich Biotech AG Amphiphilic taxane compositions
DK2286795T3 (en) 2002-06-26 2017-02-06 Syncore Biotechnology Co Ltd PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND
WO2004002455A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
AU2004249172A1 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
AU2004283464B8 (en) * 2003-10-15 2011-04-14 Syncore Biotechnology Co., Ltd Method of administering cationic liposomes comprising an active drug
JP2007517874A (ja) * 2004-01-16 2007-07-05 バーンズ−ジューイッシュ ホスピタル 標的化アテローム性動脈硬化症治療法
AU2006243337B2 (en) * 2005-05-04 2011-09-29 Syncore Biotechnology Co., Ltd Method of administering a cationic liposomal preparation comprising paclitaxel
ES2609388T3 (es) 2006-03-22 2017-04-20 Syncore Biotechnology Co., Ltd Tratamiento del cáncer de mama triple negativo a receptores
ES2447465T3 (es) 2008-03-05 2014-03-12 Baxter International Inc. Partículas de superficie modificada y métodos para la administración dirigida de fármacos
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US9706903B2 (en) 2009-06-18 2017-07-18 Endochoice, Inc. Multiple viewing elements endoscope system with modular imaging units
DE102009032658A1 (de) * 2009-07-09 2011-01-13 Forschungszentrum Jülich GmbH Mischung amphipathischer Moleküle und Verfahren zur Zellmembranmodifikation durch Fusion
KR101007925B1 (ko) * 2009-10-07 2011-01-14 건일제약 주식회사 경구용 지질 나노입자 및 그의 제조방법
KR102653436B1 (ko) * 2016-10-28 2024-03-29 르 라보레또레 쎄르비에르 암의 치료에서 사용하기 위한 리포솜 제형
KR102250123B1 (ko) 2019-11-25 2021-05-10 주식회사 현대케피코 무단 변속기의 제한 목표 기어비 학습 방법
KR102261482B1 (ko) 2019-12-10 2021-06-07 주식회사 현대케피코 무단 변속기의 킥다운 시프트 직후 구동 풀리 제어 압력 보정 방법 및 장치

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5202352A (en) * 1990-08-08 1993-04-13 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis-inhibiting substance
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO1993018751A1 (en) * 1992-03-23 1993-09-30 Georgetown University Liposome encapsulated taxol and a method of using the same
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
SI0703909T1 (en) * 1993-06-11 2000-08-31 Pharmacia & Upjohn Company Delta 6,7 -taxols antineoplastic use and pharmaceutical compositions containing them
JP4850985B2 (ja) * 1993-07-29 2012-01-11 アメリカ合衆国 微小管安定化剤を用いたアテローム性動脈硬化症または再狭窄症の治療方法
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5641755A (en) * 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
DE19605274A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
AU735900B2 (en) * 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US5935937A (en) * 1996-06-19 1999-08-10 Fox Chase Cancer Center Compositions and methods for inducing apoptosis
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
WO2000047235A2 (en) * 1999-02-10 2000-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of stimulating angiogenesis
WO2003037337A1 (en) * 2001-10-30 2003-05-08 Novartis Ag Depot formulations of iloperidone and a star polymer

Also Published As

Publication number Publication date
CN1378443A (zh) 2002-11-06
ZA200201555B (en) 2003-04-30
CZ2002850A3 (cs) 2003-04-16
CA2383412A1 (en) 2001-03-15
WO2001017508A1 (en) 2001-03-15
EA200200229A1 (ru) 2003-06-26
HUP0202669A3 (en) 2004-06-28
KR100591767B1 (ko) 2006-06-23
EP1210065B1 (en) 2006-05-03
KR20030038530A (ko) 2003-05-16
AU7122900A (en) 2001-04-10
EA005923B1 (ru) 2005-08-25
MXPA02002579A (es) 2003-10-14
JP4848113B2 (ja) 2011-12-28
EE200200127A (et) 2003-04-15
CN1235567C (zh) 2006-01-11
DE60027730D1 (de) 2006-06-08
WO2001017508A9 (en) 2002-10-03
ATE324867T1 (de) 2006-06-15
IL148372A0 (en) 2002-09-12
IL148372A (en) 2007-09-20
HUP0202669A2 (hu) 2004-05-28
PL203128B1 (pl) 2009-08-31
US20100226970A1 (en) 2010-09-09
HK1046506A1 (en) 2003-01-17
DE60027730T2 (de) 2007-03-29
EP1210065A4 (en) 2004-04-28
JP2010280667A (ja) 2010-12-16
HK1046506B (zh) 2006-08-25
EP1210065A1 (en) 2002-06-05
JP2003514768A (ja) 2003-04-22
AU782714B2 (en) 2005-08-25
ES2258471T3 (es) 2006-09-01
PL354721A1 (en) 2004-02-09
CA2383412C (en) 2010-02-02

Similar Documents

Publication Publication Date Title
BR0013866A (pt) Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicos
BR9808018A (pt) Composições de lipìdio catiÈnico tendo como alvo células endoteliais angiogênicas
Cochard et al. Cholinergic traits in the neural crest: acetylcholinesterase in crest cells of the chick embryo
Goldenberg et al. Evidence for a transport carrier of nitrogen mustard in nitrogen mustard-sensitive and-resistant L5178Y lymphoblasts
Coolican et al. Effect of L-alpha-phosphatidylinositol on a vascular smooth muscle Ca2+-dependent protease. Reduction of the Ca2+ requirement for autolysis.
Battistini et al. RGD peptide‐drug conjugates as effective dual targeting platforms: recent advances
BR9805954A (pt) Linhas de solução de auto-escorvamento e um método e sistema para usar as mesmas
ES2399267T3 (es) Suministro selectivo de moléculas al interior de las células o marcación de células en zonas enfermas de tejidos usando un péptido transmembrana sensible a su entorno
BR9813202A (pt) Processo de administração de genes a células da pele que apresentam antìgenos
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
Hur et al. Effect of oligoarginine conjugation on the antiwrinkle activity and transdermal delivery of GHK peptide
de Boer et al. Internalization of vitronectin-thrombin-antithrombin complex by endothelial cells leads to deposition of the complex into the subendothelial matrix
Lozano et al. An abietane diterpene from Salvia cuspidata and some new derivatives are active against Trypanosoma cruzi
DE69929467D1 (de) Modifizierte antikörper und antikörper-fragmente mit verlängerter aktivitätsdauer
DE69130569D1 (de) Mit psoralen konjugierte methylphosphonat-oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie
Inestrosa et al. A membrane-associated dimer of acetylcholinesterase from Xenopus skeletal muscle is solubilized by phosphatidylinositol-specific phospholipase C
Ofek et al. Rational design of multifunctional polymer therapeutics for cancer theranostics
Gonzalez-Gronow et al. Plasminogen activation stimulates an increase in intracellular calcium in human synovial fibroblasts.
Durigan et al. Effects of alternagin-C from Bothrops alternatus on gene expression and activity of metalloproteinases in regenerating skeletal muscle
BR0009064A (pt) Plantas apresentando capacidade reprodutiva modificada
Gasperi-Campani et al. Mitochondrial DNA D-loop as a new target of Saporin 6 nuclease activity
Wilkins-Port et al. Degradation of distinct forms of multimeric vitronectin by human fibroblasts
DE60138762D1 (de) Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren
Meyer et al. The lipophilic muramyltripeptide MTP-PE, a biological response modifier, is an activator of protein kinase C
ITMI931082A1 (it) Coniugati di farmaci antivirali ad attivita' epatotropica, relativi veicolanti e composizioni farmaceutiche che li contengono

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 9/127

Ipc: A61K 9/127 (2009.01), A61K 31/337 (2009.01), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S)8O, 13, 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]